ALK-Abelló Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Peter Halling

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	3.3yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

CEO

Peter Halling (46 yo)

1.3yrs

Tenure

Mr. Peter Halling is President & CEO of ALK-Abelló A/S from 2023. Mr. Peter Halling serves as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experience from working in...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Claus Solje	Executive VP	less than a year	kr.14.86m	no data
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	11.9yrs	kr.6.51m	0.020% DKK 5.7m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.1yrs	kr.7.18m	no data
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	kr.350.00k	no data
Peter Halling	President & CEO	1.3yrs	no data	no data
Per Plotnikof	VP of Corporate Communications	no data	no data	no data
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.1yrs	no data	no data
Christian Houghton	Head of Product Supply	5.3yrs	no data	no data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 0OIR's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.3yrs	kr.350.00k	no data
Jesper Hoiland	Independent Director	1.1yrs	kr.366.00k	no data
Lene Skole-Sorensen	Vice Chairman of the Board	10.3yrs	kr.900.00k	no data
Anders Hedegaard	Independent Chairman of the Board	4.1yrs	kr.1.33m	no data
Lars Holmqvist	Director	9.1yrs	kr.446.00k	no data
Gitte Aabo	Independent Director	3.1yrs	kr.523.00k	no data
Alan Main	Independent Director	2.1yrs	kr.450.00k	no data
Bertil Lindmark	Independent Director	3.1yrs	kr.500.00k	no data
Nanna Carlson	Employee Representative Director	5.1yrs	kr.350.00k	no data
Johan Smedsrud	Employee Representative Director	5.1yrs	kr.350.00k	no data
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.1yrs	kr.270.00k	no data

4.1yrs

Average Tenure

60yo

Average Age

Experienced Board: 0OIR's board of directors are considered experienced (4.1 years average tenure).

ALK-Abelló Management

Management criteria checks 2/4

Key information

Recent management updates

Insider recently sold kr.9.0m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

Insider recently sold kr.9.0m worth of stock

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Investor sentiment improves as stock rises 36%

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Investor sentiment improves as stock rises 58%

Investor sentiment improves as stock rises 60%

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

Investor sentiment improves as stock rises 87%

New major risk - Share price stability

Investor sentiment improves as stock rises 92%

Investor sentiment improves as stock rises 79%

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Investor sentiment improves as stock rises 81%

Investor sentiment improves as stock rises 80%

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Investor sentiment improves as stock rises 102%

Investor sentiment improves as stock rises 111%

Investor sentiment improves as stock rises 106%

Investor sentiment deteriorates as stock falls 16%

Alk-Abelló A/S Announces Executive Changes

Now 20% undervalued after recent price drop

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Investor sentiment improves as stock rises 83%

Investor sentiment improves as stock rises 71%

Now 21% undervalued after recent price drop

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Investor sentiment improves as stock rises 80%

Now 23% undervalued after recent price drop

Investor sentiment improves as stock rises 43%

Investor sentiment improves as stock rises 49%

Investor sentiment improves as stock rises 40%

Now 23% undervalued

Investor sentiment improves as stock rises 44%

ALK Announces Management Changes

Full year 2022 earnings released

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investor sentiment improves as stock rises 51%

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

Investor sentiment improved over the past week

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr.0.24 (vs kr.0.17 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Now 24% undervalued after recent price drop

Second quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Now 21% undervalued after recent price drop

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 20% undervalued after recent price drop

Alk-Abelló A/S Announces Executive Changes

First quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

ALK Expects to Submit Registration Application in China for its House Dust Mite (HDM) Sublingual Allergy Immunotherapy (Slit) Tablet Already in 2022

Full year 2021 earnings: Revenues in line with analyst expectations